Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)

Inclusion Criteria

• Main inclusion criteria include: - Histologically proven, metastatic or locally advanced non resectable, or recurrent post-surgery GIST - Naïve patient or patient previously treated with imatinib as neoadjuvant/adjuvant who relapsed after imatinib discontinuation - c-Kit (CD117) positive tumours detected by immuno-histochemically or PDGFR positive if c-Kit negative Main exclusion criteria include: - Patient previously treated by tyrosine kinase inhibitors except imatinib in case of inclusion criteria - Patient treated for a cancer other than GIST within 5 years before enrolment, with the exception of basal cell carcinoma or cervical cancer in situ - Patient with active central nervous system (CNS) metastasis or with history of CNS metastasis